Larry Miller, Apnimed CEO
May 19, 2025 06:00 AM EDTUpdated 06:24 AM
Startups
R&D

Ap­n­imed posts first set of Phase 3 sleep ap­nea re­sults, aims for ap­proval fil­ing in 2026

Kyle LaHucik

Senior Reporter

Ap­n­imed’s oral drug met the ef­fi­ca­cy bar in the first of two Phase 3 stud­ies in ob­struc­tive sleep ap­nea, the biotech said Mon­day morn­ing. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Re­gen­eron plans to buy 23andMe for $256M

David Liu, Sam Stern­berg un­veil new way to in­sert big genes in hu­man cells

Ex­clu­sive: Cell­Cen­tric col­lects $120M to treat mul­ti­ple myelo­ma with a cap­sule

Prime Med­i­cine side­lines on­ly clin­i­cal pro­gram, re­places CEO and lays off some staff

FDA ap­proves No­vavax's Covid vac­cine af­ter six-week de­lay, but for a small­er pop­u­la­tion

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times